Cover Image
市場調查報告書

PharmaPoint:人類乳突病毒(HPV)預防疫苗 - 日本醫藥品的預測與市場分析

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 307131
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:人類乳突病毒(HPV)預防疫苗 - 日本醫藥品的預測與市場分析 PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 86 Pages
簡介

人類乳突病毒(HPV)的最初的疫苗接種疫苗,在2006年使用。全球人類乳突病毒(HPV)疫苗市場現在已確立,不過傳統目標群的青年女子的疫苗接種率仍低。當初,人類乳突病毒(HPV)疫苗開發為子宮頸癌的預防疫苗,並上市。近幾年,其他癌症上人類乳突病毒(HPV)的作用逐漸確認,部分國家獎勵定期性接種疫苗中也包含男性,疫苗接種層級變得廣泛。

本報告提供日本的人類乳突病毒(HPV)預防疫苗市場相關調查分析、疾病的概要與指南、競爭情形、主要藥物的詳細資訊(產品說明、安全性、有效性)、SWOT分析、銷售額預測、影響分析(趨勢、推動因素、阻礙因素)等相關系統的資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
  • 症狀

第4章 疫苗接種與獎勵接種率

  • 日本
    • 接種獎勵與政策
    • 疫苗接種率
    • 臨床診療

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介
    • Gardasil
    • Cervarix

第6章 未滿足需求和機會

  • 概要
  • 對複數HPV型的預防
  • 疫苗接種率
  • 疫苗安全性的認識
  • HPV疫苗的認識
  • HPV疫苗的價格
  • 在特定層流行的HPV型的接種率
  • 疫苗接種的遵守率
  • 無法獲得對HPV感染的終身免疫
  • 對子宮頸癌檢驗的持續性需求

第7章 開發平台評估

  • 概要
  • 臨床開發中的有潛力疫苗
  • 初期開發階段的創新HPV疫苗

第8章 市場預測

  • 日本
    • 預測
    • 主要的活動
    • 推動因素、障礙

第9章 附錄

圖表

目錄
Product Code: GDHC232CFR

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

GlobalData expects the HPV vaccines market in Japan to diminish over the short term, as the decision of Japan's MHLW to remove its active recommendations for HPV vaccination will severely affect vaccine uptake in the country. Ongoing decisions on the status of HPV vaccination will impact upon HPV vaccine sales in Japan over the forecast period. Even in the case of recommendations for HPV vaccination being reinstated, it is likely that their suspension will have a long-term negative impact on HPV vaccine uptake in the country.

Scope

  • Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Prophylactic Human Papillomavirus Vaccines disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in the Japan

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Japan
    • 4.1.1. Vaccination Recommendations and Policies
    • 4.1.2. Vaccination Coverage
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles
    • 5.3.1. Gardasil
    • 5.3.2. Cervarix

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Protection against Multiple HPV Types
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Vaccine Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Perception of Vaccine Safety
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Awareness of HPV Vaccination
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Affordability of HPV Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Coverage of HPV Types Prevalent in Certain Populations
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. Vaccine Compliance Rates
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity
  • 6.9. Lifelong Protection from HPV Infection Not Established
    • 6.9.1. Unmet Need
    • 6.9.2. Gap Analysis
    • 6.9.3. Opportunity
  • 6.10. Ongoing Need for Cervical Cancer Screening
    • 6.10.1. Unmet Need
    • 6.10.2. Gap Analysis
    • 6.10.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Vaccines in Clinical Development
    • 7.2.1. Xiamen Innovax (Bivalent Vaccine)
  • 7.3. Innovative HPV Vaccines in Early Development
    • 7.3.1. Low-Cost HPV Vaccines
    • 7.3.2. Universal HPV Vaccines

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccine Approval versus Routine Schedule Inclusion
    • 9.4.3. Vaccines Included
    • 9.4.4. Vaccine Launch Dates and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Author(s)
    • 9.6.1. Author(s)
    • 9.6.2. Therapy Area Director
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Histological Progression Towards Cervical Cancer
  • Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms
  • Table 3: Marketed Vaccines for HPV, 2014
  • Table 4: Product Profile - Gardasil
  • Table 5: Phase III Efficacy Trials - Gardasil
  • Table 6: Safety Profile - Gardasil
  • Table 7: Gardasil SWOT Analysis, 2014
  • Table 8: Product Profile - Cervarix
  • Table 9: Phase III Efficacy Trials - Cervarix
  • Table 10: Safety Profile - Cervarix
  • Table 11: Cervarix SWOT Analysis, 2014
  • Table 12: Overall Unmet Needs - Current and Future Level of Attainment
  • Table 13: HPV Vaccines - Phase Pipeline, 2014
  • Table 14: Bivalent Vaccine (Xiamen Innovax) SWOT Analysis, 2014
  • Table 15: Sales Forecasts ($) for HPV Vaccines in Japan, 2012-2022
  • Table 16: Key Events Impacting Sales for HPV Vaccines in Japan, 2012-2022
  • Table 17: Japan HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 18: Key Launch Dates
  • Table 19: Key Patent Expiries
  • Table 20: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Historical and Projected HPV Vaccination Coverage (%) in Japan among 16-Year-Old Females, 2012-2022
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022
  • Figure 3: Sales for HPV Vaccines in Japan by Vaccine Class, 2012-2022
Back to Top